BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Phase 4

Completed

Conditions: Chronic Phase Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2012-08-09

Last Posted Date: 2016-11-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT01660906

Locations: 🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸
Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, United States
🇰🇷
Local Institution, Seoul, Korea, Republic of

and more 3 locations

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Drug: Sorafenib
Drug: Ipilimumab

First Posted Date: 2012-08-07

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 659

Registration Number: NCT01658878

Locations: 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸
Local Institution - 0008, Los Angeles, California, United States
🇺🇸
Local Institution - 0048, Washington, District of Columbia, United States

and more 57 locations

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Completed

Conditions: Kidney Transplantation
Transplantation, Kidney

Interventions: Drug: Calcineurin inhibitors (CNI)
Drug: Belatacept

First Posted Date: 2012-08-03

Last Posted Date: 2022-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 775

Registration Number: NCT01656343

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: 5-Fluorouracil (5FU)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Leucovorin
Drug: Irinotecan
Drug: BMS-906024

First Posted Date: 2012-07-31

Last Posted Date: 2020-01-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 141

Registration Number: NCT01653470

Locations: 🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇨🇦
Local Institution, Ottawa, Quebec, Canada

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Phase 1

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: BMS-852927
Drug: Placebo

First Posted Date: 2012-07-27

Last Posted Date: 2013-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 97

Registration Number: NCT01651273

Locations: 🇩🇪
Local Institution, Neuss, Germany

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Phase 3

Completed

Conditions: Squamous Cell Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Docetaxel

First Posted Date: 2012-07-17

Last Posted Date: 2022-12-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 272

Registration Number: NCT01642004

Locations: 🇺🇸
Local Institution - 0003, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0017, Seattle, Washington, United States
🇺🇸
Local Institution - 0001, Seattle, Washington, United States

and more 121 locations

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Biological: Elotuzumab
Biological: Thalidomide
Biological: Dexamethasone
Biological: Cyclophosphamide

First Posted Date: 2012-07-02

Last Posted Date: 2017-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 51

Registration Number: NCT01632150

Locations: 🇪🇸
Local Institution, Zaragoza, Spain

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2

Withdrawn

Conditions: Hepatitis C Virus

Interventions: Drug: Daclatasvir
Drug: BMS-986094
Drug: Ribavirin
Drug: Placebo for BMS-986094

First Posted Date: 2012-06-28

Last Posted Date: 2014-05-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01629732

Locations: 🇺🇸
Local Institution, Orlando, Florida, United States

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Phase 1

Completed

Conditions: Neoplasms by Site

Interventions: Biological: Denenicokin
Biological: Nivolumab

First Posted Date: 2012-06-28

Last Posted Date: 2015-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT01629758

Locations: 🇺🇸
Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States

and more 2 locations

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Daclatasvir
Drug: Simeprevir
Drug: Ribavirin

First Posted Date: 2012-06-27

Last Posted Date: 2017-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT01628692

Locations: 🇪🇸
Local Institution, Valencia, Spain
🇺🇸
Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy